Clinical Trial Update: Study of AMG 330 in Combination With Pembrolizumab in Adult With Relapsed or Refractory Acute Myeloid Leukemia [Phase 1]

View source ↗

Summary

Phase 1 study of AMG 330 in combination with pembrolizumab in adults with relapsed or refractory acute myeloid leukemia has been terminated; results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia

Drugs mentioned

• AMG 330
• Pembrolizumab (pembrolizumab)

Snippet

Sponsor: Amgen | Conditions: Relapsed or Refractory Acute Myeloid Leukemia | Phase 1 | Status: TERMINATED | Results posted: 2024-03-08